Changing strategies for target therapy in gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Suk-young | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.date.accessioned | 2021-09-04T03:43:36Z | - |
dc.date.available | 2021-09-04T03:43:36Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-01-21 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89773 | - |
dc.description.abstract | In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.subject | PHASE-II TRIAL | - |
dc.subject | LAPATINIB PLUS PACLITAXEL | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | BREAST-CANCER | - |
dc.subject | JUNCTION ADENOCARCINOMA | - |
dc.subject | OPEN-LABEL | - |
dc.subject | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject | 1ST-LINE TREATMENT | - |
dc.subject | 2ND-LINE THERAPY | - |
dc.subject | RESISTANT BREAST | - |
dc.title | Changing strategies for target therapy in gastric cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.identifier.doi | 10.3748/wjg.v22.i3.1179 | - |
dc.identifier.scopusid | 2-s2.0-84961352156 | - |
dc.identifier.wosid | 000368552100022 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROENTEROLOGY, v.22, no.3, pp.1179 - 1189 | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.title | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 22 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1179 | - |
dc.citation.endPage | 1189 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | LAPATINIB PLUS PACLITAXEL | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | JUNCTION ADENOCARCINOMA | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | 2ND-LINE THERAPY | - |
dc.subject.keywordPlus | RESISTANT BREAST | - |
dc.subject.keywordAuthor | Advanced gastric cancer | - |
dc.subject.keywordAuthor | Target therapy | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Strategy | - |
dc.subject.keywordAuthor | Signal pathway | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.